天津医药

天津医药 ›› 2018, Vol. 46 ›› Issue (1): 77-80.doi: 10.11958/20170695

• 临床研究 • 上一篇    下一篇

ABO 血型与卵巢癌患者预后的关系

李慧 1，王丹 2，张学慧 1△   

  1. 1 天津医科大学肿瘤医院检验科，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究 中心（邮编 300060）；2 天津中医药大学第一附属医院检验科
  • 收稿日期:2017-06-14 修回日期:2017-11-21 出版日期:2018-01-15 发布日期:2018-01-16
  • 通讯作者: 李慧 E-mail:2934890952@qq.com
  • 作者简介:李慧（1985），女，硕士研究生，医师，主要从事检验医学方面研究

The association study on ABO blood types and prognosis of patients with ovarian cancer

LI Hui1, WANG Dan2, ZHANG Xue-hui1△   

  1. 1 Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, China; 2 Department of Clinical Laboratory, the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
  • Received:2017-06-14 Revised:2017-11-21 Published:2018-01-15 Online:2018-01-16

PDF (PC)

3846

摘要： 目的 探讨 ABO 血型及其他相关因素对卵巢癌患者预后的影响。方法 回顾性分析天津医科大学肿瘤 医院 2007 年 12 月—2011 年 7 月采用根治性手术治疗的 153 例卵巢癌患者的临床病理资料和血型分布，其中 A 型 血 45 例（29.4%）、B 型血 43 例（28.1%）、O 型 50 例（32.7%），AB 型血 15 例（9.8%）。分析不同血型患者临床特征的 差异并对患者进行随访（末次随访时间 2017 年 6 月）。采用 Kaplan-Meier 法绘制生存曲线，Log-rank 法比较不同血 型间总生存率及无病生存率的差异，Cox 回归分析卵巢癌患者预后的影响因素。结果 （1）不同血型的患者年龄、月 经情况、复发和转移、临床分期、CA-125 水平以及辅助治疗等临床特征比较差异均无统计学意义（均 P > 0.05）。（2）O 型和 B 型血患者总生存率和无病生存率明显高于 A 型和 AB 型血患者（Log rank χ2 分别为 9.571、8.213，均 P < 0.05）。Cox 回归分析显示，ABO 血型是卵巢癌患者预后的影响因素，AB 型血的患者预后较差（B 型 vs. AB 型 HR= 0.339，95% CI：0.138~0.830；O 型 vs. AB 型 HR=0.343，95%CI：0.137~0.855）。结论 ABO 血型与卵巢癌患者的生存 状况相关，可用于评价卵巢癌患者的预后。

关键词: 卵巢肿瘤, ABO 血型系统, 预后, 总生存期, 无病生存期

Abstract: Objective To explore the influence of ABO blood type and other related factors on the prognosis in patients with ovarian cancer. Methods The clinical and pathological data and ABO blood types of 153 patients with ovarian cancer who were undergone radical surgery from December 2007 to July 2011 in Tianjin Medical University Cancer Institute and Hospital were retrospectively analyzed. Among them, there were 45 cases (29.4%) of blood type A, 43 cases (28.1%) of type B, 50 cases (32.7%) of type O, and 15 cases (9.8%) of type AB. The clinical characteristics of patients with different blood group types were analyzed, and the patients were followed up (the last follow-up time was June 2017). Kaplan-Meier method was used to draw the survival curve, and the Log-rank method was used to compare the differences between the total survival and disease-free survival rates in different blood groups. Cox regression analysis was performed to explore the prognostic factors in patients with ovarian cancer. Results (1) There were no statistically significant differences in the clinical features of different blood types, such as age, menstrual condition, recurrence, metastasis, clinical staging, CA- 125 level, and adjuvant treatment (P＞0.05). (2) The total survival rate and disease-free survival rate were significantly higher in patients of O and B blood types than those in patients of A and AB blood types (Log rank χ2=9.571 and 8.213 respectively, all P＜0.05). Cox regression analysis showed that ABO blood group type was an influential factor in the prognosis of ovarian cancer patients, and patients with AB blood group showed a poorer prognosis (type B vs. type AB HR= 0.339, 95%CI: 0.138-0.830, type O vs. type AB HR=0.343, 95% CI: 0.137-0.855). Conclusion ABO blood type is related to the survival of ovarian cancer patients, and which can be used to evaluate the prognosis in patients of ovarian cancer.

Key words: ovarian neoplasms, ABO blood-group system, prognosis, overall survival, disease free survival